We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
- Authors
Pardanani, Animesh; Gotlib, Jason R; Jamieson, Catriona; Cortes, Jorge E; Talpaz, Moshe; Stone, Richard M; Silverman, Michael H; Gilliland, D Gary; Shorr, Jolene; Tefferi, Ayalew
- Abstract
Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and constitutional symptoms. Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 7, p789
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.32.8021